Clinical Trial Site

Heidelberg 69120

2 studies enrolling now · 15 studies all time

What they study most

ANCA-Associated Vasculitis, Amyloid Neuropathies, Amyloid Neuropathies, Familial, Amyloidosis, Amyloidosis, Hereditary, Amyloidosis, Hereditary, Transthyretin-Related, Atypical Hemolytic-Uremic Syndrome, End Stage Renal Disease, Familial Amyloid Polyneuropathies, Familial Transthyretin Cardiac Amyloidosis, Genetic Disease, Kidney Diseases

Studies at this site

• TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Recruiting now
• Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD — Recruiting now
• Atypical Hemolytic-Uremic Syndrome (aHUS) Registry — Recruiting now
• HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Running, not enrolling
• HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) — Completed
• Long Term Extension Study in Patients With Primary Hyperoxaluria — Running, not enrolling
• A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis — Completed
• Natural History of Patients With PH3 and a History of Stone Events — Completed
• A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 — Completed
• APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis — Completed
• The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) — Completed
• Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery — Stopped early
• Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients — Completed
• The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment — Completed
• ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) — Completed